NCT03570931View on ClinicalTrials.gov

A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

November 5, 2018

Primary Completion Date

August 9, 2020

Study Completion Date

June 30, 2022

Conditions
Infantile Neuroaxonal Dystrophy
Interventions
DRUG

RT001

RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 960 mg of RT001.

Trial Locations (2)

94158

University of California San Francisco, Benioff Children's Hospital, San Francisco

07960

Jacobs Levy Genomics and Research Program, Morristown

All Listed Sponsors
lead

Biojiva LLC

INDUSTRY